HSPA5 and Autoimmunity: We hypothesize that administrating pharmacological levels of IRL201805 can promote a greater immunosuppressive activity in APCs (monocyte/macrophage, DCs), which, in turn, activate Tregs that are primed to respond to self‐antigen (GRP78/BiP) aiding resolution of inflammation during autoimmunity (Corrrigall et al., paper in preparation).